-
Recent Posts
- Lumbosacral spinal cord epidural stimulation improves voiding function after human SCI
- Gene therapy reverses rat’s paralysis at King’s College London
- Jan-Eric Ahlfors CEO and CSO of Fortuna Fix Presented at Unite to Cure
- Marquette professor awarded $1.6 million NIH grant for spinal cord injury research
- Modulation of Receptor Protein Tyrosine Phosphatase Sigma Increases Chondroitin Sulfate Proteoglycan Degradation through Cathepsin B Secretion to Enhance Axon Outgrowth
- Translating promising strategies for bowel and bladder management in spinal cord injury
- Task specific spinal cord epidural stimulation enables independent step cycles during BWST stepping in motor complete humans
- Neurons Survive Long-Term in Pigs with Spinal Cord Injuries
- Advantages of soft subdural implants for the delivery of electrochemical neuromodulation therapies to the spinal cord.
- Synaptic connectivity between host and neural progenitor cell-derived neurons after spinal cord injury
- The Role of Cortical Plasticity in Spinal Cord Injury Recovery – David Gimbel, MD
- Alliance for Regenerative Medicine (ARM) Neuralstem Presentation
- A computational model of epidural electrical stimulation of the cervical spinal cord in non-human primates
- Cortico–reticulo–spinal circuit reorganization enables functional recovery after severe spinal cord contusion
- Serotonin receptor and dendritic plasticity in the spinal cord mediated by chronic serotonergic pharmacotherapy combined with exercise following complete SCI in the adult rat
Chris & Brandon Powell
U2FP Research & Science Report Chris Powell and her son Brandon SCI Survivor (2005)
Follow on Twitter
My TweetsSpinal Cord Injury Research and Science at Facebook
Archives
Tag Archives: Jan-Eric Ahlfors
Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders
(Newswire.com) Press Release: November 8, 2017 Fortuna Fix – Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming … Continue reading
Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board
Montreal, Canada, May 4, 2017 (Newswire.com) – Fortuna Fix Inc. (“Fortuna”), a private, clinical-stage biotech company, is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat … Continue reading
Posted in Biomaterials, Chronic Spinal Cord Injury Research, Regenerative Medicine, Rehabilitation, Spinal Research, Stem Cell Research, Unite 2 Fight Paralysis
Tagged Jan-Eric Ahlfors, MPH; and Professor James Giordano, PhD; Col. (R) Dallas Hack, PhD; Father Kevin FitzGerald, Professor Michael Fehlings
1 Comment
New World Laboratories pushes forward with clinical trial
New World Laboratories acts as its own research center, allowing it to create its own therapeutic platforms. The company focuses its efforts on three main sectors—therapeutic drugs, medical devices, and cell therapies. For example, the apoptosis program (programmed cell death) … Continue reading
